Saturday 17 October 2026
Export TIL’s income statement to Excel — free account
Instil Bio, Inc.
In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
5.91
0.22
−3.59%
Follow TIL
Instil Bio, Inc. (TIL) P/E ratio
Instil Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2020 | 0.0× | — |
| Sep 2020 | 0.0× | — |
| Jun 2020 | 0.0× | — |
| Mar 2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| VERU Veru Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| SGMOQ Sangamo Therapeutics, Inc. compare | n/m |
| CELU Celularity, Inc. compare | n/m |
| GRCE Grace Therapeutics, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| TIL Instil Bio, Inc. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)